AUTL Expense Breakdown
Autolus Therapeutics plc (AUTL). Quarter ended 2026-06-30 · each product line is listed as filed.
- 2026-06-30: Reportable $20.47M.
- 2025-06-30: Reportable $24.45M.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $20.47M |
| 2025-06-30 | $24.45M |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $465.00K |
| 2025-06-30 | $397.00K |
Operating expenses: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $89.53M |
| 2025-06-30 | $82.14M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |